Beam Therapeutics

$62.45 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Beam Therapeutics

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines based on its base editing technology, to providing life-long cures to patients suffering from diseases. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). Its programs are organized by delivery modality into three distinct pipelines: electroporation for delivery to blood cells and immune cells; lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future; and adeno-associated viral vectors (AAV), for viral delivery to the eye and central nervous system (CNS). The Company has three development candidates, such as BEAM-101, BEAM-102 and BEAM-201 in which two candidates targeting hemoglobinopathies and one candidate in T-cell therapy program.

Stock Analysis

last close $62.15
1-mo return -26.5%
3-mo return -31.5%
avg daily vol. 760.23T
52-week high 138.52
52-week low 56.34
market cap. $4.6B
forward pe -
annual div. -
roe -76.2%
ltg forecast 1.7%
dividend yield -
annual rev. $1M
inst own. 78.2%
baraka

Subscribe now for daily local and international financial news

Subscribe